Related Experiment Video
Updated: Jul 4, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Dabrafenib plus Trametinib: A breakthrough in pediatric low-grade glioma therapy
Marrium Sultan Dar1, Nayab Shahid1, Arisha Waqas1
1Department of Medicine Jinnah Sindh Medical University Karachi Pakistan.
Background And Aims:
Pediatric-type low-grade gliomas (pLGGs) are the most common solid tumors in children, with v-raf murine sarcoma viral oncogene homolog B (BRAF) mutations playing a significant role in their development. Dabrafenib and trametinib are targeted therapies that are recently approved by Food and Drug Administration for pediatric patients with pLGG harboring a BRAF V600E mutation.
Body:
This study emphasizes the role of Dabrafenib and Trametinib in pLGG. A multicenter Phase I/II trial demonstrated the superior efficacy of dabrafenib plus trametinib (D+T) compared to carboplatin plus vincristine (C+T), with higher overall response rates, clinical benefit rates, and longer progression-free survival. The safety profile of dabrafenib plus trametinib (D+T) was favorable, with fewer discontinuations and adverse events compared to the control group.
Conclusion:
The introduction of D+T as a targeted therapy represents a significant advancement in the management of pLGG, necessitating further investigations to understand its long-term consequences and optimize patient care.
Insights
Dabrafenib plus trametinib (D+T) shows superior efficacy and a favorable safety profile for pediatric low-grade gliomas (pLGG) with BRAF V600E mutations compared to traditional chemotherapy.
Area of Science:
- Pediatric Oncology
- Molecular Targeted Therapy
- Cancer Genomics
Background:
- Pediatric-type low-grade gliomas (pLGG) are the most common pediatric solid tumors.
- BRAF mutations, particularly V600E, are key drivers in pLGG development.
- Targeted therapies offer new treatment avenues for pediatric patients.
Purpose of the Study:
- To evaluate the efficacy and safety of dabrafenib plus trametinib (D+T) in pediatric patients with pLGG.
- To compare D+T with standard chemotherapy (carboplatin plus vincristine).
- To highlight advancements in pLGG management.
Main Methods:
- Multicenter Phase I/II clinical trial.
- Comparison of D+T regimen against carboplatin plus vincristine (C+T).
- Assessment of overall response rates, clinical benefit rates, and progression-free survival.
Main Results:
- Dabrafenib plus trametinib demonstrated superior efficacy compared to carboplatin plus vincristine.
- Higher overall response and clinical benefit rates were observed with D+T.
- D+T showed longer progression-free survival and a favorable safety profile with fewer adverse events.
Conclusions:
- Dabrafenib plus trametinib is an effective targeted therapy for pediatric low-grade gliomas with BRAF V600E mutations.
- This combination therapy represents a significant advancement over traditional chemotherapy.
- Further research is needed to understand long-term outcomes and optimize patient care.
